Sequella acquires exclusive worldwide rights to Pfizer’s sutezolid

theflyonthewall.com

Sequella announced that it has licensed Pfizer's exclusive worldwide rights to develop and commercialize sutezolid, a Phase 2 oxazolidinone antibiotic currently in development for the treatment of tuberculosis, TB.

View Comments (0)